Last reviewed · How we verify
Len-TACE
Len-TACE combines lenvatinib (a multi-kinase inhibitor) with transarterial chemoembolization (TACE) to target hepatocellular carcinoma through dual mechanisms of kinase inhibition and localized chemotherapy delivery.
Len-TACE combines lenvatinib (a multi-kinase inhibitor) with transarterial chemoembolization (TACE) to target hepatocellular carcinoma through dual mechanisms of kinase inhibition and localized chemotherapy delivery. Used for Hepatocellular carcinoma (HCC), unresectable or advanced.
At a glance
| Generic name | Len-TACE |
|---|---|
| Sponsor | Second Affiliated Hospital of Guangzhou Medical University |
| Drug class | Multi-kinase inhibitor (combined with transarterial chemoembolization) |
| Target | FGFR, VEGFR, RET, KIT |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lenvatinib inhibits multiple receptor tyrosine kinases (FGFR, VEGFR, RET, KIT) to suppress tumor angiogenesis and growth signaling. When combined with TACE—a minimally invasive procedure delivering chemotherapy directly to the tumor via hepatic artery embolization—the approach provides both systemic kinase inhibition and concentrated local chemotherapy, potentially improving efficacy in hepatocellular carcinoma.
Approved indications
- Hepatocellular carcinoma (HCC), unresectable or advanced
Common side effects
- Hypertension
- Diarrhea
- Fatigue
- Nausea
- Hepatic impairment
Key clinical trials
- Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC (NA)
- Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC (PHASE2)
- Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT (PHASE2)
- Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT (PHASE3)
- Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
- Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study) (PHASE3)
- Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT
- DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Len-TACE CI brief — competitive landscape report
- Len-TACE updates RSS · CI watch RSS
- Second Affiliated Hospital of Guangzhou Medical University portfolio CI